|
A Randomized, Double-Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine (RAISE) |
Ramucirumab |
I4T-MC-JVBB |
NCT01183780 |
Colorectal Cancer |
Phase 3 |
|
|
Not available |
|
|
December 2016 |